When it comes to the clinical-stage immunotherapy company discussed in today’s article, the author notes that “Despite being years away from making the jump from clinical to a commercial stage company, there have been numerous instances in the past several years of the stock seeing 100% or greater returns over periods of three months or less.” Given this, and with…
The pharmaceutical company featured in today’s article, known for its innovative drug pipeline, is a late-stage biotech focused on developing novel, oral, small-molecule drugs for rare and serious diseases. Having gained 153.8% over the past year and 60.1% year-to-date, is this a good biotech stock to own? For a look at the factors that could influence its performance in the near…
“Far from a dead company, this may be one of the best held secrets in the biotech landscape,” declares the author of today’s article of the little-followed biotechnology company they highlight: an “antibody discovery company that could have the potential to revolutionize the process for discovering and rapidly advancing new therapies.” For more, CLICK HERE.
With several exciting product candidates in its pipeline that could achieve blockbuster status, the author of today’s article believes that the clinical-stage biotech that he highlights, which is focused on developing treatments for disorders that affect the central nervous system, is a better bet than an investment that’s all the rage these days: bitcoin. For the biotech in question and…
While the small biotech company featured in today’s article is not working on solving the health problem of the day – COVID-19 – it is solving a major problem that affects one in eight couples and is more prevalent than diabetes, asthma and depression. And with the company having “a clear-cut mission, great management, and a history of revenue growth”,…
The clinical-stage biotech highlighted in today’s article, dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders, has been one of the hottest biotech stocks this year. And after a run-up that has generated triple-digit returns, there are a number of factors that could help propel it to even higher highs from here. For more on this…
UBS just initiated coverage on nine biotech stocks, four of which its analysts have given ‘Buy’ ratings – and two of those, the analysts believe, could soar by more than 50%. For these four biotech stocks that investors should buy, according to UBS, as well as the five biotech stocks that the firm initiated coverage on at a ‘Neutral’ rating,…
As investors attempt to identify the COVID-19 vaccine stock that will beat all the others, biotech has become one of the hottest sectors, with the S&P Biotech SPDR ETF having jumped nearly 80% since hitting its March low. Today’s article offers an analysis of three specific biotech stocks and insights on what to do with each if you are considering…
“The premise here is simple: biotech investing is just as it was before COVID-19 and as it will be when the pandemic is finally over,” begins the author of today’s article. If one accepts this premise, what does that mean for investing in the three fronts of the war on the coronavirus (testing, treatment and vaccination)? For the author’s overview…
A clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics and a clinical- stage therapeutics company developing regenerative therapies for neurological diseases such as Alzheimer’s disease and Parkinson’s disease are among seven new biotech stocks to watch highlighted in today’s article, which also highlights new stocks to watch in the tech, defense, and real estate sectors. For these…